{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:31:42Z","timestamp":1789497102281,"version":"build-2803163510"},"reference-count":239,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00895-2","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:21:45Z","timestamp":1772259705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions"],"prefix":"10.1186","volume":"14","author":[{"given":"Zhan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhuo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"1","key":"895_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, et al. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. Mol Cancer. 2024;23(1):131.","journal-title":"Mol Cancer"},{"issue":"3","key":"895_CR2","first-page":"189","volume":"4","author":"S Zhu","year":"2024","unstructured":"Zhu S. CAR-T in cancer therapeutics and updates. J Natl Cancer Cent. 2024;4(3):189\u201394.","journal-title":"J Natl Cancer Cent"},{"issue":"3","key":"895_CR3","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168\u201378.","journal-title":"Lancet Oncol"},{"issue":"7","key":"895_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021;22(7):427\u201347.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"895_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"895_CR6","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, et al. Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"issue":"1","key":"895_CR7","first-page":"100","volume":"2","author":"VG Kravets","year":"2017","unstructured":"Kravets VG, Zhang Y, Sun H. Chimeric-Antigen-Receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100\u201313.","journal-title":"J Immunol Res Ther"},{"issue":"5","key":"895_CR8","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.","journal-title":"Clin Transl Immunol"},{"key":"895_CR9","doi-asserted-by":"crossref","unstructured":"Harrer DC, et al. CAR Triggered release of type-1 interferon limits CAR T-cell activities by an artificial negative autocrine loop. Cells. 2022;11(23).","DOI":"10.3390\/cells11233839"},{"issue":"4","key":"895_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/med4.37","volume":"1","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Oncogenic viral antigens for engineered T cell immunotherapy: challenges and opportunities. Med Adv. 2023;1(4):306\u201317.","journal-title":"Med Adv"},{"key":"895_CR11","doi-asserted-by":"publisher","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, et al. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15:1335424.","journal-title":"Front Immunol"},{"key":"895_CR12","doi-asserted-by":"publisher","first-page":"104751","DOI":"10.1016\/j.critrevonc.2025.104751","volume":"211","author":"A Suchiita","year":"2025","unstructured":"Suchiita A, Sonkar SC. Revolutionizing immunotherapy: the next frontier in CAR T-cell engineering. Crit Rev Oncol Hematol. 2025;211:104751.","journal-title":"Crit Rev Oncol Hematol"},{"key":"895_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","volume":"319","author":"TR Abreu","year":"2020","unstructured":"Abreu TR, et al. Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 2020;319:246\u201361.","journal-title":"J Control Release"},{"issue":"1","key":"895_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int. 2025;25(1):313.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"895_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","volume":"18","author":"N Jiang","year":"2025","unstructured":"Jiang N, et al. Recent advances in universal chimeric antigen receptor T cell therapy. J Hematol Oncol. 2025;18(1):82.","journal-title":"J Hematol Oncol"},{"key":"895_CR16","doi-asserted-by":"publisher","first-page":"1448752","DOI":"10.3389\/fimmu.2024.1448752","volume":"15","author":"J Gallego-Valle","year":"2024","unstructured":"Gallego-Valle J, et al. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-\u03b6) based on biotin-bound monomeric Streptavidin for potential tumor immunotherapy. Front Immunol. 2024;15:1448752.","journal-title":"Front Immunol"},{"key":"895_CR17","doi-asserted-by":"publisher","first-page":"124779","DOI":"10.1016\/j.ijpharm.2024.124779","volume":"666","author":"M Fan","year":"2024","unstructured":"Fan M, et al. Nanoparticle-mediated universal CAR-T therapy. Int J Pharm. 2024;666:124779.","journal-title":"Int J Pharm"},{"key":"895_CR18","doi-asserted-by":"publisher","first-page":"1354825","DOI":"10.3389\/fimmu.2024.1354825","volume":"15","author":"R Tao","year":"2024","unstructured":"Tao R, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol. 2024;15:1354825.","journal-title":"Front Immunol"},{"key":"895_CR19","doi-asserted-by":"publisher","first-page":"103354","DOI":"10.1016\/j.ebiom.2021.103354","volume":"67","author":"ES Atsavapranee","year":"2021","unstructured":"Atsavapranee ES, Billingsley MM, Mitchell MJ. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. EBioMedicine. 2021;67:103354.","journal-title":"EBioMedicine"},{"key":"895_CR20","first-page":"377","volume":"33","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. Bioact Mater. 2024;33:377\u201395.","journal-title":"Bioact Mater"},{"key":"895_CR21","doi-asserted-by":"crossref","unstructured":"Lee A. Obecabtagene autoleucel: first approval. Mol Diagn Ther. 2025.","DOI":"10.1007\/s40291-025-00771-z"},{"issue":"14","key":"895_CR22","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390.","journal-title":"Theranostics"},{"key":"895_CR23","doi-asserted-by":"publisher","first-page":"1041073","DOI":"10.3389\/fphar.2022.1041073","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Activation of cancer immunotherapy by nanomedicine. Front Pharmacol. 2022;13:1041073.","journal-title":"Front Pharmacol"},{"issue":"10","key":"895_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.31083\/j.fbl2910349","volume":"29","author":"N Dhas","year":"2024","unstructured":"Dhas N, et al. Nanoengineered Platform-Based Microenvironment-Triggered immunotherapy in cancer treatment. Front Biosci (Landmark Ed). 2024;29(10):349.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"895_CR25","doi-asserted-by":"publisher","first-page":"27934","DOI":"10.31083\/FBL27934","volume":"30","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Cui Y, Sun Y. Brain-targeting nanoparticle drug delivery systems for brain tumors. Front Biosci (Landmark Ed). 2025;30(1):27934.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"895_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12943-025-02476-7","volume":"24","author":"D Shang","year":"2025","unstructured":"Shang D, et al. Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives. Mol Cancer. 2025;24(1):281.","journal-title":"Mol Cancer"},{"issue":"3","key":"895_CR27","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, et al. Ionizable lipid Nanoparticle-Mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20(3):1578\u201389.","journal-title":"Nano Lett"},{"issue":"13","key":"895_CR28","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/smll.201402369","volume":"11","author":"RA Meyer","year":"2015","unstructured":"Meyer RA, et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small. 2015;11(13):1519\u201325.","journal-title":"Small"},{"key":"895_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","volume":"353","author":"IS Pinto","year":"2023","unstructured":"Pinto IS, Cordeiro RA, Faneca H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy. J Control Release. 2023;353:196\u2013215.","journal-title":"J Control Release"},{"issue":"4","key":"895_CR30","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1021\/nn500962q","volume":"8","author":"LK Bogart","year":"2014","unstructured":"Bogart LK, et al. Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano. 2014;8(4):3107\u201322.","journal-title":"ACS Nano"},{"issue":"1","key":"895_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16(1):25\u201336.","journal-title":"Nat Nanotechnol"},{"issue":"9","key":"895_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12032-025-02928-6","volume":"42","author":"YA Albalawi","year":"2025","unstructured":"Albalawi YA. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. Med Oncol. 2025;42(9):378.","journal-title":"Med Oncol"},{"issue":"4","key":"895_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"895_CR34","doi-asserted-by":"publisher","first-page":"217083","DOI":"10.1016\/j.canlet.2024.217083","volume":"597","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, et al. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the sphinx? Cancer Lett. 2024;597:217083.","journal-title":"Cancer Lett"},{"key":"895_CR35","doi-asserted-by":"publisher","first-page":"0045","DOI":"10.34133\/bmr.0045","volume":"28","author":"G Yu","year":"2024","unstructured":"Yu G, et al. Recent advancements in biomaterials for chimeric antigen receptor T cell immunotherapy. Biomater Res. 2024;28:0045.","journal-title":"Biomater Res"},{"issue":"8","key":"895_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.hlife.2024.06.002","volume":"2","author":"L Yan","year":"2024","unstructured":"Yan L, et al. Boosting CAR-T cell therapy with CRISPR technology. hLife. 2024;2(8):380\u201396.","journal-title":"hLife"},{"issue":"9","key":"895_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387.","journal-title":"Blood"},{"key":"895_CR38","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163.","journal-title":"Front Immunol"},{"issue":"1","key":"895_CR39","doi-asserted-by":"publisher","first-page":"e3066","DOI":"10.1002\/btpr.3066","volume":"37","author":"E Harris","year":"2021","unstructured":"Harris E, Elmer JJ. Optimization of electroporation and other non-viral gene delivery strategies for T cells. Biotechnol Prog. 2021;37(1):e3066.","journal-title":"Biotechnol Prog"},{"issue":"9","key":"895_CR40","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jcyt.2021.03.002","volume":"23","author":"H Kavanagh","year":"2021","unstructured":"Kavanagh H, et al. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications. Cytotherapy. 2021;23(9):852\u201360.","journal-title":"Cytotherapy"},{"issue":"7","key":"895_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41416-025-03100-7","volume":"133","author":"J Zhou","year":"2025","unstructured":"Zhou J. Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer. Br J Cancer. 2025;133(7):919\u201336.","journal-title":"Br J Cancer"},{"key":"895_CR42","doi-asserted-by":"publisher","first-page":"849759","DOI":"10.3389\/fimmu.2022.849759","volume":"13","author":"J Mi","year":"2022","unstructured":"Mi J, Ye Q, Min Y. Advances in nanotechnology development to overcome current roadblocks in CAR-T therapy for solid tumors. Front Immunol. 2022;13:849759.","journal-title":"Front Immunol"},{"key":"895_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, et al. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"895_CR44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"895_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"2","key":"895_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"895_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803\u201310.","journal-title":"Nat Med"},{"issue":"9","key":"895_CR48","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","volume":"7","author":"X Li","year":"2023","unstructured":"Li X, et al. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Eng. 2023;7(9):1129\u201341.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"895_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, et al. Single-Cell analyses identify brain mural cells expressing CD19 as potential Off-Tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126\u2013e14217.","journal-title":"Cell"},{"key":"895_CR50","doi-asserted-by":"crossref","unstructured":"Jess J, et al. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023;11(6).","DOI":"10.1136\/jitc-2022-005898"},{"key":"895_CR51","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown BD, et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-Cell therapy: can we optimize early diagnosis? Front Oncol. 2021;11:634445.","journal-title":"Front Oncol"},{"issue":"17","key":"895_CR52","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","volume":"28","author":"C Diorio","year":"2022","unstructured":"Diorio C, et al. Comprehensive serum proteome profiling of cytokine release syndrome and immune effector Cell-Associated neurotoxicity syndrome patients with B-Cell ALL receiving CAR T19. Clin Cancer Res. 2022;28(17):3804\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"895_CR53","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41563-023-01646-6","volume":"22","author":"N Gong","year":"2023","unstructured":"Gong N, et al. In situ pegylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater. 2023;22(12):1571\u201380.","journal-title":"Nat Mater"},{"issue":"7","key":"895_CR54","first-page":"e4381","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, et al. Immune effector Cell-Associated hemophagocytic Lymphohistiocytosis-Like syndrome. Transpl Cell Ther. 2023;29(7):e4381\u201343816.","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"895_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"AD Posey Jr","year":"2024","unstructured":"Posey AD Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10(8):687\u201395.","journal-title":"Trends Cancer"},{"key":"895_CR56","doi-asserted-by":"crossref","unstructured":"De Marco RC, Monzo HJ, Ojala PM. CAR T cell therapy: a versatile living drug. Int J Mol Sci. 2023;24(7).","DOI":"10.3390\/ijms24076300"},{"issue":"7","key":"895_CR57","first-page":"1973","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M, et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973\u201387.","journal-title":"Bioact Mater"},{"issue":"4","key":"895_CR58","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.fmre.2025.01.011","volume":"5","author":"N Shen","year":"2025","unstructured":"Shen N, et al. Targeted delivery and controlled release of polymeric nanomedicines for tumor therapy. Fundam Res. 2025;5(4):1349\u201368.","journal-title":"Fundam Res"},{"key":"895_CR59","doi-asserted-by":"crossref","unstructured":"Ding L, et al. Polymer-based drug delivery systems for cancer therapeutics. Polym (Basel). 2024;16(6).","DOI":"10.3390\/polym16060843"},{"issue":"2","key":"895_CR60","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ijpharm.2013.06.022","volume":"453","author":"L Wu","year":"2013","unstructured":"Wu L, et al. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior. Int J Pharm. 2013;453(2):533\u201340.","journal-title":"Int J Pharm"},{"key":"895_CR61","doi-asserted-by":"crossref","unstructured":"Morarasu S, et al. Targeted cancer therapy via pH-functionalized nanoparticles: a scoping review of methods and outcomes. Gels. 2022;8(4).","DOI":"10.3390\/gels8040232"},{"issue":"9","key":"895_CR62","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.7150\/thno.42260","volume":"11","author":"L Zou","year":"2021","unstructured":"Zou L, et al. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy. Theranostics. 2021;11(9):4171\u201386.","journal-title":"Theranostics"},{"key":"895_CR63","doi-asserted-by":"publisher","first-page":"124600","DOI":"10.1016\/j.ijpharm.2024.124600","volume":"664","author":"M Ji","year":"2024","unstructured":"Ji M, et al. Redox-sensitive disulfide-bridged self-assembled nanoparticles of dexamethasone with high drug loading for acute lung injury therapy. Int J Pharm. 2024;664:124600.","journal-title":"Int J Pharm"},{"issue":"4","key":"895_CR64","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1021\/acsami.6b15232","volume":"9","author":"Z Duan","year":"2017","unstructured":"Duan Z, et al. Stimuli-Sensitive biodegradable and amphiphilic block Copolymer-Gemcitabine conjugates Self-Assemble into a nanoscale vehicle for cancer therapy. ACS Appl Mater Interfaces. 2017;9(4):3474\u201386.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"33","key":"895_CR65","doi-asserted-by":"publisher","first-page":"8430","DOI":"10.1016\/j.biomaterials.2013.07.037","volume":"34","author":"Y Yang","year":"2013","unstructured":"Yang Y, et al. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 2013;34(33):8430\u201343.","journal-title":"Biomaterials"},{"key":"895_CR66","doi-asserted-by":"publisher","first-page":"101906","DOI":"10.1016\/j.mito.2024.101906","volume":"78","author":"M Dowaidar","year":"2024","unstructured":"Dowaidar M. Cell-penetrating peptides with nanoparticles hybrid delivery vectors and their uptake pathways. Mitochondrion. 2024;78:101906.","journal-title":"Mitochondrion"},{"issue":"6","key":"895_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.molmed.2021.03.003","volume":"27","author":"KL Swingle","year":"2021","unstructured":"Swingle KL, Hamilton AG, Mitchell MJ. Lipid Nanoparticle-Mediated delivery of mRNA therapeutics and vaccines. Trends Mol Med. 2021;27(6):616\u20137.","journal-title":"Trends Mol Med"},{"issue":"6","key":"895_CR68","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1021\/acsabm.4c00103","volume":"7","author":"F Giulimondi","year":"2024","unstructured":"Giulimondi F, et al. Optimizing transfection efficiency in CAR-T cell manufacturing through multiple administrations of Lipid-Based nanoparticles. ACS Appl Bio Mater. 2024;7(6):3746\u201357.","journal-title":"ACS Appl Bio Mater"},{"key":"895_CR69","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"P Prazeres","year":"2023","unstructured":"Prazeres P, et al. Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int J Nanomed. 2023;18:5891\u2013904.","journal-title":"Int J Nanomed"},{"issue":"2","key":"895_CR70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2007.11.023","volume":"261","author":"OV Chumakova","year":"2008","unstructured":"Chumakova OV, et al. Composition of PLGA and PEI\/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 2008;261(2):215\u201325.","journal-title":"Cancer Lett"},{"key":"895_CR71","doi-asserted-by":"publisher","first-page":"101653","DOI":"10.1016\/j.mtbio.2025.101653","volume":"32","author":"L Xu","year":"2025","unstructured":"Xu L, et al. Gold nanoparticles modulate macrophage polarization to promote skeletal muscle regeneration. Mater Today Bio. 2025;32:101653.","journal-title":"Mater Today Bio"},{"key":"895_CR72","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3762\/bjnano.9.98","volume":"9","author":"J Jeevanandam","year":"2018","unstructured":"Jeevanandam J, et al. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050\u201374.","journal-title":"Beilstein J Nanotechnol"},{"issue":"25","key":"895_CR73","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1016\/j.biomaterials.2010.05.009","volume":"31","author":"J Lipka","year":"2010","unstructured":"Lipka J, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010;31(25):6574\u201381.","journal-title":"Biomaterials"},{"issue":"8","key":"895_CR74","doi-asserted-by":"publisher","first-page":"e2301300","DOI":"10.1002\/smtd.202301300","volume":"8","author":"T Hu","year":"2024","unstructured":"Hu T, et al. Automating CAR-T transfection with micro and Nano-Technologies. Small Methods. 2024;8(8):e2301300.","journal-title":"Small Methods"},{"issue":"1","key":"895_CR75","doi-asserted-by":"publisher","first-page":"e1900286","DOI":"10.1002\/biot.201900286","volume":"15","author":"PD Mo\u00e7o","year":"2020","unstructured":"Mo\u00e7o PD, Aharony N, Kamen A. Adeno-Associated viral vectors for Homology-Directed generation of CAR-T cells. Biotechnol J. 2020;15(1):e1900286.","journal-title":"Biotechnol J"},{"issue":"4","key":"895_CR76","doi-asserted-by":"publisher","first-page":"e13791","DOI":"10.1111\/cpr.13791","volume":"58","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, et al. Revolutionising cancer immunotherapy: advancements and prospects in Non-Viral CAR-NK cell engineering. Cell Prolif. 2025;58(4):e13791.","journal-title":"Cell Prolif"},{"key":"895_CR77","doi-asserted-by":"crossref","unstructured":"Shi J, et al. A review on electroporation-based intracellular delivery. Molecules. 2018;23(11).","DOI":"10.3390\/molecules23113044"},{"key":"895_CR78","doi-asserted-by":"crossref","unstructured":"Lock D, et al. Automated, scaled, transposon-based production of CAR T cells. J Immunother Cancer. 2022;10(9).","DOI":"10.1136\/jitc-2022-005189"},{"issue":"12","key":"895_CR79","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1021\/acs.molpharmaceut.2c00811","volume":"19","author":"DN Yadav","year":"2022","unstructured":"Yadav DN, et al. Recent advancements in the design of nanodelivery systems of SiRNA for cancer therapy. Mol Pharm. 2022;19(12):4506\u201326.","journal-title":"Mol Pharm"},{"issue":"1","key":"895_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-024-01574-1","volume":"17","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, et al. Lipid-based nanosystems: the next generation of cancer immune therapy. J Hematol Oncol. 2024;17(1):53.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"895_CR81","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer. 2025;24(1):160.","journal-title":"Mol Cancer"},{"key":"895_CR82","first-page":"29","volume":"17","author":"X Han","year":"2022","unstructured":"Han X, et al. Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy. Bioact Mater. 2022;17:29\u201348.","journal-title":"Bioact Mater"},{"key":"895_CR83","doi-asserted-by":"publisher","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, et al. The Past, Present, and future of Non-Viral CAR T cells. Front Immunol. 2022;13:867013.","journal-title":"Front Immunol"},{"issue":"2","key":"895_CR84","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.19988","volume":"206","author":"Z Chen","year":"2025","unstructured":"Chen Z, et al. mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells. Br J Haematol. 2025;206(2):628\u201343.","journal-title":"Br J Haematol"},{"key":"895_CR85","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","volume":"361","author":"SH El Moukhtari","year":"2023","unstructured":"El Moukhtari SH, et al. Lipid nanoparticles for SiRNA delivery in cancer treatment. J Control Release. 2023;361:130\u201346.","journal-title":"J Control Release"},{"issue":"1","key":"895_CR86","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley MM, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 2022;22(1):533\u201342.","journal-title":"Nano Lett"},{"issue":"10","key":"895_CR87","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li YR, et al. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;25(10):725\u201344.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"895_CR88","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","volume":"20","author":"S Shin","year":"2023","unstructured":"Shin S, et al. Nanoparticle-Based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023;20(3):371\u201387.","journal-title":"Tissue Eng Regen Med"},{"key":"895_CR89","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2147\/IJN.S195828","volume":"14","author":"S Song","year":"2019","unstructured":"Song S, et al. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses. Int J Nanomed. 2019;14:2465\u201383.","journal-title":"Int J Nanomed"},{"key":"895_CR90","doi-asserted-by":"publisher","first-page":"113779","DOI":"10.1016\/j.jconrel.2025.113779","volume":"383","author":"M Wu","year":"2025","unstructured":"Wu M, et al. Sequentially conquering transfection Obstacles of primary human T cells via non-classical lipid nanoparticles delivering reformative transposon system. J Control Release. 2025;383:113779.","journal-title":"J Control Release"},{"key":"895_CR91","doi-asserted-by":"crossref","unstructured":"Xu Q, et al. The impact of surface modifier on magnetic nanoparticle properties and their application in CD3\u2009+\u2009T cell separation. Langmuir. 2024.","DOI":"10.1021\/acs.langmuir.4c01332"},{"issue":"2","key":"895_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41551-021-00820-y","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting. Nat Biomed Eng. 2022;6(2):108\u201317.","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"895_CR93","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1021\/acs.nanolett.2c01018","volume":"22","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Nanoparticle amplification labeling for High-Performance magnetic cell sorting. Nano Lett. 2022;22(12):4774\u201383.","journal-title":"Nano Lett"},{"key":"895_CR94","doi-asserted-by":"publisher","first-page":"115448","DOI":"10.1016\/j.addr.2024.115448","volume":"214","author":"E Garbayo","year":"2024","unstructured":"Garbayo E, et al. RNA-loaded nanoparticles for the treatment of hematological cancers. Adv Drug Deliv Rev. 2024;214:115448.","journal-title":"Adv Drug Deliv Rev"},{"key":"895_CR95","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"key":"895_CR96","doi-asserted-by":"crossref","unstructured":"Bot A, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2025.","DOI":"10.69645\/NEPO7828"},{"key":"895_CR97","doi-asserted-by":"crossref","unstructured":"Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Reviews Mater. 2017;2(10).","DOI":"10.1038\/natrevmats.2017.56"},{"issue":"8","key":"895_CR98","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"895_CR99","doi-asserted-by":"publisher","first-page":"e2310078","DOI":"10.1002\/adma.202310078","volume":"36","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy. Adv Mater. 2024;36(5):e2310078.","journal-title":"Adv Mater"},{"key":"895_CR100","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307.","journal-title":"J Control Release"},{"issue":"11","key":"895_CR101","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):e2304378.","journal-title":"Small"},{"issue":"3","key":"895_CR102","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.7150\/thno.40291","volume":"10","author":"W Ma","year":"2020","unstructured":"Ma W, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281\u201395.","journal-title":"Theranostics"},{"key":"895_CR103","first-page":"422","volume":"34","author":"S Yaman","year":"2024","unstructured":"Yaman S, et al. Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles. Bioact Mater. 2024;34:422\u201335.","journal-title":"Bioact Mater"},{"key":"895_CR104","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.2147\/IJN.S200284","volume":"14","author":"M Wu","year":"2019","unstructured":"Wu M, et al. Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy. Int J Nanomed. 2019;14:4431\u201348.","journal-title":"Int J Nanomed"},{"issue":"27","key":"895_CR105","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CM Hu","year":"2011","unstructured":"Hu CM, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"895_CR106","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian F, et al. Immune cell Membrane-Coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17(12):e2006484.","journal-title":"Small"},{"issue":"3","key":"895_CR107","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao G, et al. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull (Beijing). 2024;69(3):354\u201366.","journal-title":"Sci Bull (Beijing)"},{"key":"895_CR108","doi-asserted-by":"crossref","unstructured":"Sayyed AA, et al. Engineering cell-derived nanovesicles for targeted immunomodulation. Nanomaterials (Basel). 2023;13(20).","DOI":"10.3390\/nano13202751"},{"issue":"1","key":"895_CR109","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","volume":"24","author":"M Wang","year":"2025","unstructured":"Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: opportunities, Obstacles and challenges. Mol Cancer. 2025;24(1):26.","journal-title":"Mol Cancer"},{"key":"895_CR110","doi-asserted-by":"publisher","first-page":"1611423","DOI":"10.3389\/fimmu.2025.1611423","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu F. Opportunities, Obstacles and challenges of nano-immunotherapy in melanoma. Front Immunol. 2025;16:1611423.","journal-title":"Front Immunol"},{"key":"895_CR111","doi-asserted-by":"crossref","unstructured":"Neo SY, et al. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. J Immunother Cancer. 2023;11(4).","DOI":"10.1136\/jitc-2022-006434"},{"issue":"1","key":"895_CR112","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"MC Vo","year":"2025","unstructured":"Vo MC, et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol Oncol. 2025;18(1):91.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"895_CR113","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1097\/CM9.0000000000003706","volume":"138","author":"M Wang","year":"2025","unstructured":"Wang M, et al. Innovative strategies for improving CAR-T cell therapy: A nanomedicine perspective. Chin Med J (Engl). 2025;138(21):2769\u201382.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"895_CR114","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/cas.70023","volume":"116","author":"Y Ito","year":"2025","unstructured":"Ito Y, et al. Feasibility of intratumoral administration with EPHB4-CAR-T cells for the treatment of oral squamous cell carcinoma. Cancer Sci. 2025;116(5):1227\u201338.","journal-title":"Cancer Sci"},{"key":"895_CR115","doi-asserted-by":"crossref","unstructured":"Papa S, et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer. 2023;11(6).","DOI":"10.1136\/jitc-2023-007162"},{"issue":"14","key":"895_CR116","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"895_CR117","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312.","journal-title":"Nat Med"},{"key":"895_CR118","doi-asserted-by":"publisher","first-page":"121341","DOI":"10.1016\/j.biomaterials.2021.121341","volume":"281","author":"Y Luo","year":"2022","unstructured":"Luo Y, et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341.","journal-title":"Biomaterials"},{"issue":"23","key":"895_CR119","doi-asserted-by":"publisher","first-page":"e1900192","DOI":"10.1002\/adma.201900192","volume":"31","author":"Q Chen","year":"2019","unstructured":"Chen Q, et al. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv Mater. 2019;31(23):e1900192.","journal-title":"Adv Mater"},{"issue":"14","key":"895_CR120","doi-asserted-by":"publisher","first-page":"e2007494","DOI":"10.1002\/smll.202007494","volume":"17","author":"Z Chen","year":"2021","unstructured":"Chen Z, et al. Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment Photothermal-Remodeling strategy. Small. 2021;17(14):e2007494.","journal-title":"Small"},{"key":"895_CR121","doi-asserted-by":"publisher","first-page":"100615","DOI":"10.1016\/j.mtbio.2023.100615","volume":"20","author":"Y Tang","year":"2023","unstructured":"Tang Y, et al. TGF-\u03b2 blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells. Mater Today Bio. 2023;20:100615.","journal-title":"Mater Today Bio"},{"issue":"18","key":"895_CR122","doi-asserted-by":"publisher","first-page":"e2211509","DOI":"10.1002\/adma.202211509","volume":"35","author":"X Tang","year":"2023","unstructured":"Tang X, et al. Magnetic-Acoustic sequentially actuated CAR T cell microrobots for precision navigation and in situ antitumor immunoactivation. Adv Mater. 2023;35(18):e2211509.","journal-title":"Adv Mater"},{"issue":"11","key":"895_CR123","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021;5(11):1336\u201347.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"895_CR124","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez SS, et al. Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol Cancer. 2025;24(1):191.","journal-title":"Mol Cancer"},{"issue":"1","key":"895_CR125","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025;18(1):6.","journal-title":"J Hematol Oncol"},{"key":"895_CR126","doi-asserted-by":"publisher","first-page":"101626","DOI":"10.1016\/j.mtbio.2025.101626","volume":"31","author":"S Karimi","year":"2025","unstructured":"Karimi S, et al. For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy. Mater Today Bio. 2025;31:101626.","journal-title":"Mater Today Bio"},{"key":"895_CR127","doi-asserted-by":"crossref","unstructured":"Tseriotis VS, et al. ZnO-based nanoparticles for targeted cancer chemotherapy and the role of tumor microenvironment: a systematic review. Int J Mol Sci. 2025;26(17).","DOI":"10.3390\/ijms26178417"},{"issue":"21","key":"895_CR128","doi-asserted-by":"publisher","first-page":"e2206370","DOI":"10.1002\/adma.202206370","volume":"35","author":"W Zhen","year":"2023","unstructured":"Zhen W, Weichselbaum RR, Lin W. Nanoparticle-Mediated radiotherapy remodels the tumor microenvironment to enhance antitumor efficacy. Adv Mater. 2023;35(21):e2206370.","journal-title":"Adv Mater"},{"issue":"1","key":"895_CR129","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/s41467-022-30543-w","volume":"13","author":"X Guan","year":"2022","unstructured":"Guan X, et al. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 Blockade to limit post-surgical cancer recurrence and metastasis. Nat Commun. 2022;13(1):2834.","journal-title":"Nat Commun"},{"issue":"1","key":"895_CR130","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-025-03396-6","volume":"44","author":"H Xu","year":"2025","unstructured":"Xu H, et al. A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint Blockade resistance in HCC via reshaping immunosuppressive TME. J Exp Clin Cancer Res. 2025;44(1):148.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"895_CR131","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/med4.36","volume":"1","author":"D Yadav","year":"2023","unstructured":"Yadav D, Malviya R. Novel nanomaterials as photo-activated cancer diagnostics and therapy. Med Adv. 2023;1(3):190\u2013209.","journal-title":"Med Adv"},{"issue":"41","key":"895_CR132","doi-asserted-by":"publisher","first-page":"e2202161","DOI":"10.1002\/smll.202202161","volume":"18","author":"H Yuan","year":"2022","unstructured":"Yuan H, et al. Photothermal nanozymatic nanoparticles induce ferroptosis and apoptosis through tumor microenvironment manipulation for cancer therapy. Small. 2022;18(41):e2202161.","journal-title":"Small"},{"key":"895_CR133","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jconrel.2023.02.009","volume":"355","author":"F Moradi Kashkooli","year":"2023","unstructured":"Moradi Kashkooli F, et al. Ultrasound-mediated nano drug delivery for treating cancer: fundamental physics to future directions. J Control Release. 2023;355:552\u201378.","journal-title":"J Control Release"},{"issue":"9","key":"895_CR134","doi-asserted-by":"publisher","first-page":"e2308254","DOI":"10.1002\/adma.202308254","volume":"36","author":"Z Dong","year":"2024","unstructured":"Dong Z, et al. Tumor microenvironment modulating CaCO(3) -Based colloidosomal microreactors can generally reinforce cancer immunotherapy. Adv Mater. 2024;36(9):e2308254.","journal-title":"Adv Mater"},{"issue":"12","key":"895_CR135","doi-asserted-by":"publisher","first-page":"11749","DOI":"10.1021\/acsnano.3c02592","volume":"17","author":"H Li","year":"2023","unstructured":"Li H, Near-Infrared A, et al. -II fluorescent nanocatalyst for enhanced CAR T cell therapy against solid tumor by immune reprogramming. ACS Nano. 2023;17(12):11749\u201363.","journal-title":"ACS Nano"},{"key":"895_CR136","doi-asserted-by":"publisher","first-page":"122750","DOI":"10.1016\/j.biomaterials.2024.122750","volume":"312","author":"M Yazdimamaghani","year":"2025","unstructured":"Yazdimamaghani M, et al. Tumor microenvironment Immunomodulation by nanoformulated TLR 7\/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy. Biomaterials. 2025;312:122750.","journal-title":"Biomaterials"},{"issue":"1","key":"895_CR137","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262.","journal-title":"Nat Commun"},{"issue":"13","key":"895_CR138","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","volume":"78","author":"F Zhang","year":"2018","unstructured":"Zhang F, et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res. 2018;78(13):3718\u201330.","journal-title":"Cancer Res"},{"issue":"3","key":"895_CR139","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1021\/acsnano.7b00078","volume":"11","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, et al. Enhancing adoptive cell therapy of cancer through targeted delivery of Small-Molecule immunomodulators to internalizing or noninternalizing receptors. ACS Nano. 2017;11(3):3089\u2013100.","journal-title":"ACS Nano"},{"issue":"7","key":"895_CR140","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, et al. CAR-T cells Surface-Engineered with Drug-Encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res. 2018;6(7):812\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"895_CR141","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"895_CR142","doi-asserted-by":"publisher","first-page":"eaaz6579","DOI":"10.1126\/sciadv.aaz6579","volume":"6","author":"CWt Shields","year":"2020","unstructured":"Shields CWt, et al. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020;6(18):eaaz6579.","journal-title":"Sci Adv"},{"issue":"8","key":"895_CR143","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang L, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"895_CR144","doi-asserted-by":"publisher","first-page":"e2213222120","DOI":"10.1073\/pnas.2213222120","volume":"120","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2023;120(1):e2213222120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"895_CR145","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038\u201347.","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"895_CR146","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, et al. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"key":"895_CR147","doi-asserted-by":"publisher","first-page":"107628","DOI":"10.1016\/j.phrs.2025.107628","volume":"213","author":"B Xia","year":"2025","unstructured":"Xia B, et al. Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy. Pharmacol Res. 2025;213:107628.","journal-title":"Pharmacol Res"},{"issue":"1","key":"895_CR148","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12967-024-05159-x","volume":"22","author":"K Lin","year":"2024","unstructured":"Lin K, et al. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology. J Transl Med. 2024;22(1):349.","journal-title":"J Transl Med"},{"issue":"1","key":"895_CR149","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-022-01246-y","volume":"15","author":"Z Sun","year":"2022","unstructured":"Sun Z, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. J Hematol Oncol. 2022;15(1):29.","journal-title":"J Hematol Oncol"},{"key":"895_CR150","doi-asserted-by":"publisher","first-page":"107419","DOI":"10.1016\/j.pharmthera.2019.107419","volume":"205","author":"SJ Bagley","year":"2020","unstructured":"Bagley SJ, O\u2019Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. Pharmacol Ther. 2020;205:107419.","journal-title":"Pharmacol Ther"},{"issue":"15","key":"895_CR151","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148\u2013e316520.","journal-title":"Cell"},{"issue":"15","key":"895_CR152","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: Building a Bridge over troubled waters. Cell. 2022;185(15):2770\u201388.","journal-title":"Cell"},{"issue":"11","key":"895_CR153","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, et al. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32(11):3772\u201392.","journal-title":"Mol Ther"},{"key":"895_CR154","doi-asserted-by":"publisher","first-page":"120584","DOI":"10.1016\/j.biomaterials.2020.120584","volume":"268","author":"A Isser","year":"2021","unstructured":"Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 2021;268:120584.","journal-title":"Biomaterials"},{"issue":"1","key":"895_CR155","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12951-023-01900-8","volume":"21","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach. J Nanobiotechnol. 2023;21(1):159.","journal-title":"J Nanobiotechnol"},{"issue":"65","key":"895_CR156","doi-asserted-by":"publisher","first-page":"eabf4034","DOI":"10.1126\/sciimmunol.abf4034","volume":"6","author":"JR Kuchroo","year":"2021","unstructured":"Kuchroo JR, et al. The double-edged sword: Harnessing PD-1 Blockade in tumor and autoimmunity. Sci Immunol. 2021;6(65):eabf4034.","journal-title":"Sci Immunol"},{"issue":"1","key":"895_CR157","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, et al. Immune checkpoint Blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):59.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"895_CR158","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee YH, et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022;30(2):579\u201392.","journal-title":"Mol Ther"},{"issue":"722","key":"895_CR159","doi-asserted-by":"publisher","first-page":"eadg6752","DOI":"10.1126\/scitranslmed.adg6752","volume":"15","author":"S Ma","year":"2023","unstructured":"Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg6752.","journal-title":"Sci Transl Med"},{"issue":"30","key":"895_CR160","doi-asserted-by":"publisher","first-page":"e2301515","DOI":"10.1002\/adhm.202301515","volume":"12","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, et al. Ionizable lipid nanoparticles with integrated immune checkpoint Inhibition for mRNA CAR T cell engineering. Adv Healthc Mater. 2023;12(30):e2301515.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"895_CR161","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acsnano.2c04420","volume":"16","author":"ZY Al Subeh","year":"2022","unstructured":"Al Subeh ZY, et al. Lipid nanoparticle delivery of Fas plasmid restores Fas expression to suppress melanoma growth in vivo. ACS Nano. 2022;16(8):12695\u2013710.","journal-title":"ACS Nano"},{"issue":"22","key":"895_CR162","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1097\/CM9.0000000000003379","volume":"137","author":"S Tu","year":"2024","unstructured":"Tu S, et al. Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies. Chin Med J (Engl). 2024;137(22):2681\u20133.","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"895_CR163","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current Understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"895_CR164","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/cncr.70069","volume":"131","author":"D Synnott","year":"2025","unstructured":"Synnott D, et al. Cytokine release syndrome in solid tumors. Cancer. 2025;131(17):e70069.","journal-title":"Cancer"},{"issue":"1","key":"895_CR165","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1038\/s41467-025-61858-z","volume":"16","author":"F Birocchi","year":"2025","unstructured":"Birocchi F, et al. On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models. Nat Commun. 2025;16(1):9650.","journal-title":"Nat Commun"},{"issue":"1","key":"895_CR166","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","volume":"10","author":"S Yu","year":"2017","unstructured":"Yu S, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.","journal-title":"J Hematol Oncol"},{"key":"895_CR167","doi-asserted-by":"publisher","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"SH Khan","year":"2024","unstructured":"Khan SH, et al. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol. 2024;15:1489827.","journal-title":"Front Immunol"},{"issue":"9","key":"895_CR168","doi-asserted-by":"publisher","first-page":"8551","DOI":"10.1021\/acsnano.3c00906","volume":"17","author":"Z Li","year":"2023","unstructured":"Li Z, et al. A multifunctional nanoparticle mitigating cytokine storm by scavenging multiple inflammatory mediators of sepsis. ACS Nano. 2023;17(9):8551\u201363.","journal-title":"ACS Nano"},{"key":"895_CR169","doi-asserted-by":"crossref","unstructured":"Pfister F, et al. Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism. MedComm (2020). 2025;6(1):e70039.","DOI":"10.1002\/mco2.70039"},{"issue":"17","key":"895_CR170","doi-asserted-by":"publisher","first-page":"e2410975","DOI":"10.1002\/smll.202410975","volume":"21","author":"J Lim","year":"2025","unstructured":"Lim J, et al. Enhancing chimeric antigen receptor T-cell generation via microfluidic mechanoporation and lipid nanoparticles. Small. 2025;21(17):e2410975.","journal-title":"Small"},{"key":"895_CR171","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.2147\/IJN.S500520","volume":"20","author":"X Pan","year":"2025","unstructured":"Pan X, et al. Applications of mRNA delivery in cancer immunotherapy. Int J Nanomed. 2025;20:3339\u201361.","journal-title":"Int J Nanomed"},{"issue":"12","key":"895_CR172","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen NT, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424\u201334.","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"895_CR173","doi-asserted-by":"publisher","first-page":"e2205044","DOI":"10.1002\/advs.202205044","volume":"10","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Nanomodified switch induced precise and moderate activation of CAR-T cells for solid tumors. Adv Sci (Weinh). 2023;10(12):e2205044.","journal-title":"Adv Sci (Weinh)"},{"key":"895_CR174","doi-asserted-by":"publisher","first-page":"115135","DOI":"10.1016\/j.addr.2023.115135","volume":"203","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Cellular and molecular imaging of CAR-T cell-based immunotherapy. Adv Drug Deliv Rev. 2023;203:115135.","journal-title":"Adv Drug Deliv Rev"},{"key":"895_CR175","doi-asserted-by":"crossref","unstructured":"Kiru L, et al. In vivo imaging of nanoparticle-labeled CAR T cells. Proc Natl Acad Sci U S A. 2022;119(6).","DOI":"10.1073\/pnas.2102363119"},{"issue":"15","key":"895_CR176","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.7150\/thno.87248","volume":"13","author":"J Hunger","year":"2023","unstructured":"Hunger J, et al. In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma. Theranostics. 2023;13(15):5170\u201382.","journal-title":"Theranostics"},{"issue":"6","key":"895_CR177","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/RLI.0000000000000946","volume":"58","author":"WE Wu","year":"2023","unstructured":"Wu WE, et al. Multimodal in vivo tracking of chimeric antigen receptor T cells in preclinical glioblastoma models. Invest Radiol. 2023;58(6):388\u201395.","journal-title":"Invest Radiol"},{"key":"895_CR178","doi-asserted-by":"publisher","first-page":"120630","DOI":"10.1016\/j.biomaterials.2020.120630","volume":"269","author":"S Harmsen","year":"2021","unstructured":"Harmsen S, et al. A dual-modal PET\/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials. 2021;269:120630.","journal-title":"Biomaterials"},{"key":"895_CR179","doi-asserted-by":"publisher","first-page":"114361","DOI":"10.1016\/j.ejpb.2024.114361","volume":"201","author":"SK S","year":"2024","unstructured":"S SK, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. Eur J Pharm Biopharm. 2024;201:114361.","journal-title":"Eur J Pharm Biopharm"},{"key":"895_CR180","doi-asserted-by":"publisher","first-page":"105041","DOI":"10.1016\/j.critrevonc.2025.105041","volume":"217","author":"A Toro-Pedroza","year":"2025","unstructured":"Toro-Pedroza A, et al. Advancing CAR-T cell manufacturing in Latin america: current landscape, future directions, and challenges. Crit Rev Oncol Hematol. 2025;217:105041.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"895_CR181","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nm.2198","volume":"16","author":"MT Stephan","year":"2010","unstructured":"Stephan MT, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035\u201341.","journal-title":"Nat Med"},{"issue":"19","key":"895_CR182","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1039\/D3BM01265D","volume":"11","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Dual-responsive PEG-lipid polyester nanoparticles for SiRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment. Biomater Sci. 2023;11(19):6619\u201334.","journal-title":"Biomater Sci"},{"key":"895_CR183","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2017.05.014","volume":"258","author":"E Zupan\u010di\u010d","year":"2017","unstructured":"Zupan\u010di\u010d E, et al. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. J Control Release. 2017;258:182\u201395.","journal-title":"J Control Release"},{"issue":"1","key":"895_CR184","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"895_CR185","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6(7):102209.","journal-title":"Cell Rep Med"},{"issue":"3","key":"895_CR186","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/2643-3230.BCD-23-0240","volume":"6","author":"F Luciani","year":"2025","unstructured":"Luciani F, et al. Advancing CAR T-cell therapies with artificial intelligence: opportunities and challenges. Blood Cancer Discov. 2025;6(3):159\u201362.","journal-title":"Blood Cancer Discov"},{"key":"895_CR187","doi-asserted-by":"crossref","unstructured":"Stewart MD, et al. Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery. J Immunother Cancer. 2025;13(12).","DOI":"10.1136\/jitc-2025-013518"},{"issue":"2","key":"895_CR188","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/med4.62","volume":"2","author":"GM Raj","year":"2024","unstructured":"Raj GM, Dananjayan S, Gudivada KK. Applications of artificial intelligence and machine learning in clinical medicine: what Lies ahead? Med Adv. 2024;2(2):202\u20134.","journal-title":"Med Adv"},{"issue":"3","key":"895_CR189","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/med4.76","volume":"2","author":"F Chen","year":"2024","unstructured":"Chen F, et al. Toward bridging gaps in patient navigation: A study on the adoption of artificial intelligence technologies. Med Adv. 2024;2(3):274\u201383.","journal-title":"Med Adv"},{"key":"895_CR190","doi-asserted-by":"publisher","first-page":"1635159","DOI":"10.3389\/fimmu.2025.1635159","volume":"16","author":"JC Baena","year":"2025","unstructured":"Baena JC, et al. Smart CAR-T nanosymbionts: archetypes and proto-models. Front Immunol. 2025;16:1635159.","journal-title":"Front Immunol"},{"key":"895_CR191","doi-asserted-by":"crossref","unstructured":"Khairnar SV, et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics. 2022;14(9).","DOI":"10.3390\/pharmaceutics14091886"},{"key":"895_CR192","doi-asserted-by":"crossref","unstructured":"M\u00fclhopt S, et al. Characterization of nanoparticle batch-to-batch variability. Nanomaterials (Basel). 2018;8(5).","DOI":"10.3390\/nano8050311"},{"issue":"14","key":"895_CR193","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/17435889.2024.2359355","volume":"19","author":"RF Silveira","year":"2024","unstructured":"Silveira RF, et al. The role of artificial intelligence and data science in nanoparticles development: a review. Nanomed (Lond). 2024;19(14):1271\u201383.","journal-title":"Nanomed (Lond)"},{"issue":"10","key":"895_CR194","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1021\/acsabm.3c00527","volume":"6","author":"X Ma","year":"2023","unstructured":"Ma X, et al. Interpretable XGBoost-SHAP model predicts nanoparticles delivery efficiency based on tumor genomic mutations and nanoparticle properties. ACS Appl Bio Mater. 2023;6(10):4326\u201335.","journal-title":"ACS Appl Bio Mater"},{"issue":"11","key":"895_CR195","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.jpha.2024.100996","volume":"14","author":"R Maharjan","year":"2024","unstructured":"Maharjan R, et al. Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches. J Pharm Anal. 2024;14(11):100996.","journal-title":"J Pharm Anal"},{"key":"895_CR196","doi-asserted-by":"publisher","first-page":"157454","DOI":"10.1016\/j.cej.2024.157454","volume":"500","author":"A Mottafegh","year":"2024","unstructured":"Mottafegh A, Na JJ, Sharma GS, Kim V. AI-assisted autonomous manufacturing of tailored drug-loaded nanoparticles by multi-step continuous-flow platform. Chem Eng J. p. 2024;500:157454.","journal-title":"Chem Eng J"},{"key":"895_CR197","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.omtm.2023.101114","volume":"31","author":"N Francis","year":"2023","unstructured":"Francis N, et al. Development of an automated manufacturing process for large-scale production of autologous T cell therapies. Mol Ther Methods Clin Dev. 2023;31:101114.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"895_CR198","doi-asserted-by":"publisher","first-page":"913287","DOI":"10.3389\/fmed.2022.913287","volume":"9","author":"S Hort","year":"2022","unstructured":"Hort S, et al. Toward rapid, widely available autologous CAR-T cell therapy - artificial intelligence and automation enabling the smart manufacturing hospital. Front Med (Lausanne). 2022;9:913287.","journal-title":"Front Med (Lausanne)"},{"key":"895_CR199","doi-asserted-by":"publisher","first-page":"614324","DOI":"10.3389\/fbioe.2021.614324","volume":"9","author":"P Grzesik","year":"2021","unstructured":"Grzesik P, Warth SC. One-Time optimization of advanced T cell culture media using a machine learning pipeline. Front Bioeng Biotechnol. 2021;9:614324.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"895_CR200","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-022-06722-0","volume":"196","author":"FM Howard","year":"2022","unstructured":"Howard FM, et al. Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022;196(1):57\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"895_CR201","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-023-01654-z","volume":"25","author":"JR Peterson","year":"2023","unstructured":"Peterson JR, et al. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer. Breast Cancer Res. 2023;25(1):54.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"895_CR202","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1007\/s00330-025-11390-x","volume":"35","author":"H Kim","year":"2025","unstructured":"Kim H, et al. Digital mammography with AI-based computer-aided diagnosis to predict neoadjuvant chemotherapy response in HER2-positive and triple-negative breast cancer patients: comparison with MRI. Eur Radiol. 2025;35(9):5671\u201384.","journal-title":"Eur Radiol"},{"issue":"4","key":"895_CR203","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, et al. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"key":"895_CR204","doi-asserted-by":"publisher","first-page":"1501010","DOI":"10.3389\/fcimb.2024.1501010","volume":"14","author":"S Imani","year":"2024","unstructured":"Imani S, et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol. 2024;14:1501010.","journal-title":"Front Cell Infect Microbiol"},{"key":"895_CR205","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jconrel.2024.08.015","volume":"374","author":"K Mi","year":"2024","unstructured":"Mi K, et al. Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models. J Control Release. 2024;374:219\u201329.","journal-title":"J Control Release"},{"issue":"1","key":"895_CR206","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/acs.molpharmaceut.3c00880","volume":"21","author":"A Yousfan","year":"2024","unstructured":"Yousfan A, et al. A comprehensive study on nanoparticle drug delivery to the brain: application of machine learning techniques. Mol Pharm. 2024;21(1):333\u201345.","journal-title":"Mol Pharm"},{"issue":"10","key":"895_CR207","doi-asserted-by":"publisher","first-page":"nwad214","DOI":"10.1093\/nsr\/nwad214","volume":"10","author":"L Zhou","year":"2023","unstructured":"Zhou L, et al. STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy. Natl Sci Rev. 2023;10(10):nwad214.","journal-title":"Natl Sci Rev"},{"issue":"1","key":"895_CR208","doi-asserted-by":"publisher","first-page":"22048","DOI":"10.1038\/s41598-024-72629-z","volume":"14","author":"Y Akhtar","year":"2024","unstructured":"Akhtar Y, et al. Machine learning- a new paradigm in nanoparticle-mediated drug delivery to cancerous tissues through the human cardiovascular system enhanced by magnetic field. Sci Rep. 2024;14(1):22048.","journal-title":"Sci Rep"},{"issue":"7","key":"895_CR209","doi-asserted-by":"publisher","first-page":"e0282573","DOI":"10.1371\/journal.pone.0282573","volume":"18","author":"Y Tong","year":"2023","unstructured":"Tong Y, et al. Prediction of lymphoma response to CAR T cells by deep learning-based image analysis. PLoS ONE. 2023;18(7):e0282573.","journal-title":"PLoS ONE"},{"key":"895_CR210","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2020.01.009","volume":"320","author":"LL Israel","year":"2020","unstructured":"Israel LL, et al. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J Control Release. 2020;320:45\u201362.","journal-title":"J Control Release"},{"key":"895_CR211","doi-asserted-by":"crossref","unstructured":"Luo D, et al. Recent development of gold nanoparticles as contrast agents for cancer diagnosis. Cancers (Basel). 2021;13(8).","DOI":"10.3390\/cancers13081825"},{"key":"895_CR212","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejmp.2021.05.036","volume":"87","author":"M Oumano","year":"2021","unstructured":"Oumano M, Yu H. A deep learning approach to gold nanoparticle quantification in computed tomography. Phys Med. 2021;87:83\u20139.","journal-title":"Phys Med"},{"issue":"1","key":"895_CR213","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1039\/c2ib20093g","volume":"5","author":"P Bhatnagar","year":"2013","unstructured":"Bhatnagar P, et al. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb). 2013;5(1):231\u20138.","journal-title":"Integr Biol (Camb)"},{"issue":"28","key":"895_CR214","doi-asserted-by":"publisher","first-page":"e2506746","DOI":"10.1002\/advs.202506746","volume":"12","author":"M Chen","year":"2025","unstructured":"Chen M, et al. Development of a DNA Aptamer-Based approach to noninvasively image CAR-T cells in vivo and traceless enrichment in vitro. Adv Sci (Weinh). 2025;12(28):e2506746.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"895_CR215","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1038\/s41551-025-01415-7","volume":"9","author":"V Morath","year":"2025","unstructured":"Morath V, et al. PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes. Nat Biomed Eng. 2025;9(11):1886\u2013906.","journal-title":"Nat Biomed Eng"},{"key":"895_CR216","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.trsl.2025.08.002","volume":"283","author":"M He","year":"2025","unstructured":"He M, et al. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging. Transl Res. 2025;283:3\u201312.","journal-title":"Transl Res"},{"key":"895_CR217","doi-asserted-by":"publisher","first-page":"106084","DOI":"10.1016\/j.compbiomed.2022.106084","volume":"150","author":"R Zhang","year":"2022","unstructured":"Zhang R, et al. RCMNet: A deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022;150:106084.","journal-title":"Comput Biol Med"},{"key":"895_CR218","doi-asserted-by":"publisher","first-page":"114124","DOI":"10.1016\/j.bios.2022.114124","volume":"206","author":"TA Nguyen-Le","year":"2022","unstructured":"Nguyen-Le TA, et al. Nanosensors in clinical development of CAR-T cell immunotherapy. Biosens Bioelectron. 2022;206:114124.","journal-title":"Biosens Bioelectron"},{"key":"895_CR219","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.toxlet.2019.05.016","volume":"312","author":"I Furxhi","year":"2019","unstructured":"Furxhi I, et al. Machine learning prediction of nanoparticle in vitro toxicity: A comparative study of classifiers and ensemble-classifiers using the Copeland index. Toxicol Lett. 2019;312:157\u201366.","journal-title":"Toxicol Lett"},{"key":"895_CR220","doi-asserted-by":"publisher","first-page":"153697","DOI":"10.1016\/j.tox.2023.153697","volume":"501","author":"M Ahmadi","year":"2024","unstructured":"Ahmadi M, Ayyoubzadeh SM, Ghorbani-Bidkorpeh F. Toxicity prediction of nanoparticles using machine learning approaches. Toxicology. 2024;501:153697.","journal-title":"Toxicology"},{"issue":"1","key":"895_CR221","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","volume":"42","author":"D Cort\u00e9s-Selva","year":"2021","unstructured":"Cort\u00e9s-Selva D, et al. Innate and Innate-Like cells: the future of chimeric antigen receptor (CAR) cell therapy. Trends Pharmacol Sci. 2021;42(1):45\u201359.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"895_CR222","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"key":"895_CR223","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","volume":"10","author":"D Pende","year":"2019","unstructured":"Pende D, et al. Killer Ig-Like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179.","journal-title":"Front Immunol"},{"issue":"1","key":"895_CR224","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13287-021-02406-6","volume":"12","author":"GM Robbins","year":"2021","unstructured":"Robbins GM, et al. Nonviral genome engineering of natural killer cells. Stem Cell Res Ther. 2021;12(1):350.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"895_CR225","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1073\/pnas.1614193114","volume":"114","author":"CJ McKinlay","year":"2017","unstructured":"McKinlay CJ, et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A. 2017;114(4):E448\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"895_CR226","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1182\/bloodadvances.2020002355","volume":"4","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ, et al. Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Adv. 2020;4(17):4244\u201355.","journal-title":"Blood Adv"},{"key":"895_CR227","doi-asserted-by":"publisher","first-page":"119418","DOI":"10.1016\/j.biomaterials.2019.119418","volume":"221","author":"KS Kim","year":"2019","unstructured":"Kim KS, et al. Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. Biomaterials. 2019;221:119418.","journal-title":"Biomaterials"},{"key":"895_CR228","doi-asserted-by":"crossref","unstructured":"Zhang Q, et al. Engineered mesenchymal stem cell-NK cell complexes for spatially targeted and functionally revitalized cancer immunotherapy. Adv Sci (Weinh). 2025:e09638.","DOI":"10.1002\/advs.202509638"},{"issue":"5","key":"895_CR229","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41577-020-0302-9","volume":"20","author":"MT Villanueva","year":"2020","unstructured":"Villanueva MT. Macrophages get a CAR. Nat Rev Immunol. 2020;20(5):273.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"895_CR230","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.","journal-title":"Mol Cancer"},{"issue":"43","key":"895_CR231","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, et al. Nanocomplex-Mediated in vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):e2103258.","journal-title":"Adv Mater"},{"issue":"2","key":"895_CR232","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","volume":"8","author":"Z Ye","year":"2022","unstructured":"Ye Z, et al. In vitro engineering chimeric antigen receptor macrophages and T cells by lipid Nanoparticle-Mediated mRNA delivery. ACS Biomater Sci Eng. 2022;8(2):722\u201333.","journal-title":"ACS Biomater Sci Eng"},{"issue":"7","key":"895_CR233","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol. 2023;41(7):907\u201322.","journal-title":"Trends Biotechnol"},{"key":"895_CR234","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","volume":"8","author":"S Nair","year":"2017","unstructured":"Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. Front Immunol. 2017;8:1178.","journal-title":"Front Immunol"},{"issue":"23","key":"895_CR235","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, et al. NKT cells coexpressing a GD2-Specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res. 2019;25(23):7126\u201338.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"895_CR236","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124(18):2824\u201333.","journal-title":"Blood"},{"key":"895_CR237","doi-asserted-by":"crossref","unstructured":"Simon B, et al. The generation of CAR-transfected natural killer T cells for the immunotherapy of melanoma. Int J Mol Sci. 2018;19(8).","DOI":"10.3390\/ijms19082365"},{"key":"895_CR238","doi-asserted-by":"publisher","first-page":"101893","DOI":"10.1016\/j.mtbio.2025.101893","volume":"32","author":"K Zhang","year":"2025","unstructured":"Zhang K, et al. \u03b1-GalCer-LNP Ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy. Mater Today Bio. 2025;32:101893.","journal-title":"Mater Today Bio"},{"key":"895_CR239","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","volume":"361","author":"S Douka","year":"2023","unstructured":"Douka S, et al. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells. J Control Release. 2023;361:455\u201369.","journal-title":"J Control Release"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00895-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:21:48Z","timestamp":1775571708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":239,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00895-2","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}